Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares stood at 1.08 million during the last session, with the company’s beta value hitting 2.32. At the close of trading, the stock’s price was $1.24, to imply a decrease of -3.12% or -$0.04 in intraday trading. The FATE share’s 52-week high remains $5.92, putting it -377.42% down since that peak but still an impressive 46.77% since price per share fell to its 52-week low of $0.66. The company has a valuation of $142.11M, with an average of 2.17 million shares in intraday trading volume over the past 10 days and average of 2.36 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Fate Therapeutics Inc (FATE), translating to a mean rating of 2.42. Of 8 analyst(s) looking at the stock, 1 analyst(s) give FATE a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 5 recommend it as a Buy.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
After registering a -3.12% downside in the last session, Fate Therapeutics Inc (FATE) has traded red over the past five days. The 5-day price performance for the stock is -8.15%, and 63.78% over 30 days. With these gigs, the year-to-date price performance is -24.85%. Short interest in Fate Therapeutics Inc (NASDAQ:FATE) saw shorts transact 15.59 million shares and set a 7.87 days time to cover.
The extremes give us $3 and $5 for target low and target high price respectively. As such, FATE has been trading -303.23% off suggested target high and -141.94% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -2.63% for the past 5-year period. While 2025 is set for a 7.36% return in earnings, projections for the next 5 years are at 7.78% annually.
FATE Dividends
Fate Therapeutics Inc has its next earnings report out on 2025-Mar-04. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
Fate Therapeutics Inc insiders hold 2.24% of total outstanding shares, with institutional holders owning 89.08% of the shares at 91.12% float percentage. In total, 89.08% institutions holds shares in the company, led by REDMILE GROUP, LLC. As of 2024-06-30, the company held over 13.17 million shares (or 11.2107% of shares), all amounting to roughly $43.19 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 10.57 million shares, or about 8.998% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $34.67 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Fate Therapeutics Inc (FATE) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 3.05 shares. This is just over 2.66% of the total shares, with a market valuation of $3.78 million. Data from the same date shows that the other fund manager holds a little less at 2.62, or 2.29% of the shares, all valued at about 3.25 million.
